The Company identifies and implements plan to improve its recombinant spider silk

ANN ARBOR, Mich., – January 25, 2018- Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“Company”), the leading developer of spider silk based fibers, today announced that the Company has recently implemented an expanded material performance testing procedure for its recombinant spider silk technology. This procedure is part of the Company’s efforts to continuously improve its operations and products. 

With this new expanded testing, the Company has already identified variances in material properties for its transgenic silkworm lines, which fall outside of the Company’s target ranges.  This variance is believed to be the result of genetic drift within the Company’s silkworm strains. 

In response to this new discovery, the Company has implemented an intensive selective breeding program to leverage the results of the newly established testing procedure.  The Company has also begun a cross breeding project to reinvigorate its transgenic lines with commercial silk genetics.  Combined, the expanded testing and selective breeding efforts are designed to allow the Company to more tightly control silk properties, while at the same time, creating the necessary genetic diversity within each line.  

The increased throughput and capacity for material testing, enabled by the Company’s new facilities and new testing protocol, is expected to identify even more opportunities for material and process improvements over the coming quarters.  The Company intends to use these discoveries to improve its operations and its products. 

“The expanded capacity for testing, which resulted from our decision to insource a major portion of our research operations, has already proven its significant value to the Company,” said Jon Rice, COO. “The results from performance testing, under the new testing protocol, have already been translated into an action plan.  The ability to quickly translate those results into an action plan is a great example of the value in consolidating our research and production into a single facility.  The efforts already underway to improve our testing and selective breeding should result in an improved process and more uniform final product.  Our plan is to improve quality back to our target range before spooling up for mass production.  This could cause a delay in commercialization if the other parts of our commercialization plan fall into place earlier. Uniform materials, improved quality control, and minimizing the performance variance will play an important part in our work to commercialize spider silk.  The information gained from this program will continue to inform our drive for continuous improvement.”

To view the most recent edition of Kraig’s Spider Sense quarterly newsletter and/or to sign up for Company alerts, please go to www.KraigLabs.com/newsletter.

About Kraig Biocraft Laboratories, Inc.
Kraig Biocraft Laboratories, Inc. (w), a fully reporting biotechnology company, is the leading developer of genetically engineered spider silk based fiber technologies. The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.

Cautionary Statement Regarding Forward Looking Information
Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

Ben Hansel, Hansel Capital, LLC

(720) 288-8495

ir@KraigLabs.com

ANN ARBOR, Mich., – January 19, 2018- Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“Company”), the leading developer of spider silk based fibers, today announced that the Company succeeded in creating a new hybrid transgenic silkworm at its Michigan production facility.  This is the first hybrid silkworm created at the new Michigan facility, which recently opened in October of 2017. 

This is the first new hybrid line developed in conjunction with the Company’s US Army contract and is the next step in its program to expand its commercial recombinant spider silk offerings.  The new recombinant spider silk strain combines properties from one of the Company’s best performing transgenics with a large commercial silkworm line, to produce larger cocoons and even stronger silk.

“Creating our first hybrid in the new facility is a great moment for the Company,” said Jon Rice, COO. “The transgenic line that we used, as the base for this new hybrid, has been under development for some time.  We are very eager to review the test results for this new line, as they come in.   The opportunity to soon analyze its capabilities, once transformed into a commercial line, are very exciting.”

To view the most recent edition of Kraig’s Spider Sense quarterly newsletter and/or to sign up for Company alerts, please go to www.KraigLabs.com/newsletter.

About Kraig Biocraft Laboratories, Inc.
Kraig Biocraft Laboratories, Inc. (w), a fully reporting biotechnology company is the leading developer of genetically engineered spider silk based fiber technologies. The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.

Cautionary Statement Regarding Forward Looking Information
Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

Ben Hansel, Hansel Capital, LLC

(720) 288-8495

ir@KraigLabs.com

ANN ARBOR, Mich., – January 8, 2018- Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“Company”), the leading developer of spider silk based fibers, today announced that the US ARMY has fully funded its ongoing contract to develop new recombinant spider silk fibers. The additional funding, just over $420,000, brings the total allocated funding on the contract to $1.02 million. This second phase of the Company’s contract with the US ARMY, valued at $921,000, began in July of 2017 and is focused exclusively on the development of new spider silk fibers. The Company is currently utilizing multiple approaches to create these transgenics, with performance that surpasses the original Dragon SilkTM that was produced for the baseline contract.

“The US ARMY’s choice to exercise the base contracts option period and to dramatically increase the total contract value gave us the ability to boost our research and development efforts substantially,” said Jon Rice, COO. “Under this expanded scope we are directed to develop new transgenics, with greater strength and toughness than anything we’ve ever seen before. With the allocation of the remaining contract funding, the US ARMY has now obligated all of the dollars committed in that contract award.”

About Kraig Biocraft Laboratories, Inc.
Kraig Biocraft Laboratories, Inc. (w), a fully reporting biotechnology company is the leading developer of genetically engineered spider silk based fiber technologies. The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.

Cautionary Statement Regarding Forward Looking Information
Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.
Ben Hansel, Hansel Capital, LLC
(720) 288-8495
ir@KraigLabs.com

Dear Friends,

Merry Christmas, Happy Hanukkah and Seasons Greetings to all of our Shareholders!

Christmas is a season not only of rejoicing but of reflection. — Winston Churchill

As we look forward to the New Year, let us all take a moment to reflect upon the events of 2017…

2017 was a year full of major milestones and a series of firsts for Kraig Labs.  In our first quarter, Kraig saw advancements in nearly all aspects of our production operations.  We signed a land lease and planted 2,000 mulberry trees on our own mulberry plantation in Texas, strengthening our domestic production capability base.  We held a series of successful meetings and gained strong support from foreign government officials in our efforts to open international production operations, bringing us to the verge of an international production launch.  We produced and shipped the first production batch of Dragon Silk cocoons for processing under our contract with the US Army, proving that our technology can be quickly and efficiently scaled.  But this was just the beginning.

Through the balance of the year, we have continued to make major changes and advancements to the business.  In August, Kraig announced that the US army exercised their option to increase our contract for spider silk to more than $1.0 Million, nearly ten times the original contract value.  In September, we announced the termination of our long term equity line financing with Calm Seas Capital.  This move has freed the Company to grow and explore better financing options.

In October, we more than tripled the size of our domestic production operations, moving from our pilot location in Indiana to our new research and production headquarters in Michigan.  This move has for the first time brought our research and production teams under one roof, vastly improving our efficiency and economies of scale on every level.  That effort alone has already borne fruit in the cross-pollination of ideas and training among all our staff.  Not to mention, the move was seamless, and production at the new facility was up and fully running within less than 30 days!

In the last quarter, Kraig’s team built out a laboratory, for a fraction of the cost of a traditional lab build-out, with the capacity and capability to create new and exciting transgenics.  With Kraig’s move in the third quarter and the accompanying lab build-out at the new facility, the Company has moved most of its molecular biology from the university laboratory into our own facility with our own full time staffing.  We are already working to develop the next generation designs for stronger and tougher spider silk in our new in-house laboratory. 

With so many firsts and so many advancements from the fundamentals all the way through to a million dollar contract with the US Army, one cannot help but wonder why our market valuation has lagged.  Isn’t the Company stronger after the US Army executed its million dollar contract to deliver spider silk than it was before?  It is, and remains, the opinion of Company management that our valuation remains disjointed from the fundamental reality of the accelerating progress we’re seeing in our business every day.  In particular, we have seen dramatic positive changes in our internal fundamentals over the last two quarters. 

In addition to all of the progress we’ve made domestically in production, in R&D, and in our Army contract, we are also making significant progress establishing overseas production.  We believe that production at a location with existing silk infrastructure is key to unlocking substantial value for our shareholders, better aligning the Company valuation to the fundamentals of our business, and bringing our revolutionary materials to mass market.  We believe that given the foundation we have laid in 2017, it is merely a matter of time before we are able to launch that larger scale international production.  The holdup on that front is regulatory approval, the timing of which is not within the Company’s control.

It has been said many a time before, that the holidays are the most wonderful time of the year.  That sentiment is ringing truer than ever at Kraig Biocraft Laboratories.  We are proud of the significant strides Kraig Biocraft has made in improving our technological and competitive position this year.

As we review 2017 and how far we’ve come, we look forward towards building upon that foundation and making 2018 spectacular.  We thank you for your faith and continued support.  We believe that we have the most passionate shareholders, and that you are vital to our successful navigation of this emerging industry.

2017 was full of operational and business model improvements, even if those have not yet been reflected in our valuation.  The year has brought us many moments to celebrate, and we stand on the cusp of clearing a number of significant Company milestones, including the potential for international production volumes.

We see substantial opportunity in the various markets we are targeting.  We enter 2018 on a fundamentally solid footing, with great expectations for what the New Year holds for our technology.

It is in this spirit of the holidays that we extend our warmest greetings and best wishes for the New Year.  We accomplished much in the last year, but there is no doubt in our mind that our best days are in front of us. 

The Kraig Labs’ team kindly thanks you for your trust and continuing loyalty. We hope that you are surrounded by love, and warmth, this holiday season and that the holidays bring you many reasons to smile.

Kim K Thompson                                                                              Jon Rice

Founder and Chief Executive Officer                                                Chief Operations Officer

 About Kraig Biocraft Laboratories, Inc.
Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a fully reporting biotechnology company is the leading developer of genetically engineered spider silk based fiber technologies. The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could”, “spectacular”, “dramatic”, or other words or phrases of similar import. Forward looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This letter does not constitute an offer to sell or the solicitation of an offer to buy any security.

Ben Hansel, Hansel Capital, LLC

(720) 288-8495

ir@KraigLabs.com

New Laboratory to Develop Next Generation Spider Silk

ANN ARBOR, Mich., – December 14, 2017- Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“Company”), the leading developer of spider silk based fibers, today announced that the Company has completed the build out of new laboratory space in its new research and production center.  The Company expects to begin the testing of existing spider silk formulations and the construction of new formulations before Christmas under its ongoing contract with the US Army to develop and deliver high performance spider silk polymers for protective applications. 

In just over two weeks the Company has staffed and equipped a fully functional laboratory and is now in the process of developing the next generation of spider silk products.  Consistent with the Company’s Ethos of efficiency and frugality, the lab was finished ahead of schedule, and under budget. 

“The opening of this new Lab is a watershed moment for the Company,” said Jon Rice, COO.  “Our new facility gives us the capacity to design, develop, and test new Spider Silk formulations, which give us the ability to rapidly develop new products going into 2018. We have brought on additional staff over the last 60 days, to take our ground breaking Spider Silk technology to the next level. Recent developments have reinvigorated our team, making us as excited today, as we were when we began our journey.”

About Kraig Biocraft Laboratories, Inc.
Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a fully reporting biotechnology company is the leading developer of genetically engineered spider silk based fiber technologies. The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.

Cautionary Statement Regarding Forward Looking Information
Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

Ben Hansel, Hansel Capital, LLC

(720) 288-8495

ir@KraigLabs.com

ANN ARBOR, Mich., – December 4, 2017- Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“Company”), the leading developer of spider silk based fibers, today announced that it has expanded research operations at its new Michigan facility with the appointment of a new lead molecular biologist.  In this role he will play a key part in developing the next generation of recombinant silk fibers and protein constructions as well as overseeing all aspects of our research laboratory.  Over the next 60 days the Company plans to hire additional research staff to support this role as the Company rapidly ramps up development of new and stronger transgenics and polymers. 

“After reviewing and screening numerous candidates for this crucial role, I am confident that we’ve found an ideal match,” said Jon Rice, COO.  “With excellent technical skills and a great cultural fit, he is already well on the way to making significant contributions to the team and our technology.  We expect great things from him over the coming quarter and I look forward to sharing those results with all of the Kraig Labs shareholders.”

About Kraig Biocraft Laboratories, Inc.
Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a fully reporting biotechnology company is the leading developer of genetically engineered spider silk based fiber technologies. The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.

Cautionary Statement Regarding Forward Looking Information
Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

Ben Hansel, Hansel Capital, LLC

(720) 288-8495

ir@KraigLabs.com

Happy Thanksgiving from Kraig Biocraft Laboratories. 

This week we witnessed the first silk moths emerging from cocoons that started from eggs in the new Michigan office.  This is just the first of many batches of many Silk moths we expect over the remainder of this month.  The new facility is currently housing Dragon Silk silkworms in all 5 instars’ (stages of growth) and is also rearing several other transgenic lines.  The Company expects to significantly expand throughput as we look to close out the fourth quarter on a high note. 

The Company has started hiring and training additional production staff and has hired a new a new molecular biologist, whom we’re very excited about.  He will be starting the week after thanksgiving.  

The build out of new Laboratory space in the Michigan office is well underway and equipment is already starting to come in.  Over the next several months we will be expanding our laboratory staff, equipment, space, and capabilities. 

Here are just a few of the images we took this week in the lab.

Below are Dragon Silk cocoons spun on the mounting mesh.  Within the next couple of weeks they will emerge and create the next generate of Dragon Silk silkworms

Dragon Silk Cocoons

Entering the second instar these silkworms below would fit on the tip of your finger, but are already 20 times larger than when newly hatched. 

2nd Instar Dragon Silk silkworms

Another batch is now in their third Instar, they are now half the length of your finger and the amount of food they consume is growing exponentially.  By the time they reach their 3^rd molt they will be more than 700 times their birth weight, roughly a week and a half ago.

3rd Instar Dragon Silk silkworms

Photos of emerged silk moths are always some of our favorites.  Here for Thanksgiving is a female Dragon Silk moth which emerged from cocoon this week and getting ready to take her place in growing our Dragon Silk colony.

Dragon Silk moth

2017 has been a great year for Kraig Labs and as we look forward to tomorrow’s holiday, we have much to be thankful for.  Opening our new research and production headquarter, expanding our production and research team, the follow on contract for the US Army, and opening our mulberry farm in Texas are just a few of the many significant milestones and accomplishments we’ve celebrated this year. 

From the entire Kraig Labs team, we wish you all a Happy Thanksgiving and a prosperous New Year

New fiber strains to complement the Company’s record setting Dragon Silk Technology

ANN ARBOR, Mich., – October 30, 2017- Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB)

(“Company”), the leading developer of spider silk based fibers, announced that it is now working to create a set of new custom designed transgenic silkworms under its contract with the US Army.  The Company is working with material performance objectives, defined by the customer, to develop entirely new genetically enhanced silkworm strains. 

These new silk polymers will be evaluated against defined performance requirements and the best performing materials will be scaled up to produce upwards of 100kgs of silk thread.  The Company expects the new strains to complement its record setting Dragon Silk fibers, but, with an eye on additional targeted applications, the fibers will be designed to generate even higher tensile strength.  As a result, these new enhanced fibers should provide outstanding performance in protective textile applications.

“This project is an excellent opportunity for us to demonstrate the incredible potential and power of engineered silk,” said COO Jon Rice.  “Tailoring the focus of our design efforts directly to a materials performance requirements is a perfect example of the amazing flexibility, and possibilities, of engineered proteins.  These new transgenics will be the beginning of our Enhanced Tactical Fiber (ETF) line of materials.  While a monumental moment for the Company, it is but one of many new and exciting opportunities for, spider silk, the Company, and our shareholders.”

To support this effort, the Company is hiring additional research and production staff and rapidly building out its in house lab capabilities at its Michigan based research and production center.

To view the most recent edition of Kraig’s Spider Sense quarterly newsletter and/or to sign up for Company alerts, please go to www.KraigLabs.com/newsletter   

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a fully reporting biotechnology company is the leading developer of genetically engineered spider silk based fiber technologies.

The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,”

“foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

Ben Hansel, Hansel Capital, LLC

(720) 288-8495

ir@KraigLabs.com